Microdosing Amanita Muscaria: What the Baba Masha Survey Actually Found

The Baba Masha survey is the largest collection of amanita muscaria microdosing reports that exists: over 3,000 respondents answering a 107-item questionnaire about their experiences with small, sub-perceptual doses. It is self-reported and uncontrolled, so it cannot prove anything, but it is the best picture we have of what people actually do and what they say happens.

This post lays out what the survey covered, what it found, where it falls short, and how people who microdose amanita muscaria tend to approach it. No spin in either direction.

Who is Baba Masha and what was the survey?

Baba Masha is a Russian physician and researcher who ran a large online community around amanita use. Between 2019 and 2021 she collected structured questionnaires from more than 3,000 people who had microdosed dried amanita muscaria, then published the results in a book, Microdosing with Amanita Muscaria (2022). A peer-reviewed book review in the Journal of Psychedelic Studies in 2023 summarized her work alongside two other amanita microdosing guides and described her approach as the data-driven and conservative one of the three. You can find that review at the Journal of Psychedelic Studies.

The survey is not a clinical trial. It is a big, careful self-report study, and it should be read that way.

A quick definition before going further. A microdose, in Masha's framing and in most user reports, is an amount of dried amanita small enough that you do not feel altered during the day. Anything that produces the dreamy, heavy feeling people describe from a full evening dose of dried caps is past the microdose line by definition. Users draw that line by weight and by how the material was processed, which is why the potency question keeps coming back throughout this post.

What the respondents reported

The broad finding, in the reviewer's words, was that amanita microdoses were reported to affect a wide range of complaints, wider than what is typically reported for psilocybin microdosing. Respondents most commonly described changes in mood, sleep, energy and pain perception, along with reduced cravings for alcohol and other substances in some subgroups.

A few specific patterns stood out:

• Timing changed the effect. Morning doses were more often described as energizing, and evening doses as relaxing and sleep-promoting. That tracks with what evening users say about dried caps in general.
• Effects were described as gradual. Most respondents said they noticed changes over days to weeks rather than in a single session, which is typical of microdosing reports for any substance.
• Some respondents reported nothing. A meaningful share said they felt no difference, positive or negative.

Adverse reports were mostly mild and dose-related: nausea, drowsiness at the wrong time of day, headaches, and occasional skin sensitivity. Masha's own guidance leaned heavily on staying at low amounts and using properly dried material, which is the same advice that shows up on our muscimol overview.

Where the survey falls short

It is worth being honest about the limits, because a lot of vendors are not.

• Self-selection. People who join an amanita community and fill out a 107-question form are not a random sample. They are enthusiasts, and enthusiasts report positive outcomes more often.
• No placebo, no control. Expectation effects are strong in microdosing research generally. Placebo-controlled psilocybin microdosing studies have found much smaller effects than surveys did, and there is no reason to assume amanita would be different.
• Unknown potency. Respondents used home-dried mushroom of unknown muscimol content. A "microdose" in one report could be several times stronger than the same gram weight in another. That is the main reason we HPLC test every batch of extract and caps.
• Not peer-reviewed data. The book review was peer reviewed. The survey itself was published in a book, not a journal.

So the fair reading is: thousands of people report that small doses of amanita feel useful to them, and nobody has tested that claim under controlled conditions yet. That is more than most botanicals have behind them, and much less than a medical claim would need, and we sell amanita products on the first basis, not the second.

How people microdose in practice

Masha's respondents mostly used dried, decarbed cap, typically somewhere in the range of a few hundred milligrams up to about 1 gram, and typically not every day. With a standardized 15:1 high muscimol extract, users tend to talk in muscimol milligrams instead, commonly around 1 to 3 mg. Muscimol isolate makes the milligram math cleanest but leaves no room for error, so most people start with caps or extract.

The common schedule in user reports is a few days on, a couple off, for a few weeks, then a longer break. Morning if the goal is a lift, evening if the goal is winding down. And the rule that every experienced person repeats: start at the very bottom, give it a week, and only then adjust.

Quick FAQ

Is microdosing amanita the same as microdosing psilocybin?
No. Psilocybin acts on serotonin receptors and amanita's muscimol acts on GABA-A. Users describe the two very differently, with amanita microdoses reported as calming or grounding rather than the mild stimulation people associate with psilocybin.

What did the survey say about safety?
Reported side effects at microdose levels were mostly mild and tied to taking too much or using poorly dried mushroom. Nothing in the survey removes the standard cautions: no alcohol or sedatives alongside it, and tested material from a known source like our amanita collection rather than wild-picked caps.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Amanita products are sold for adults 21+ only. This article is for educational purposes and describes traditional use and user reports, not medical advice.